Buy Velpanat

Velpanat

Velpanat: Antiviral Medication Overview

Velpanat contains the active ingredients sofosbuvir and velpatasvir. It is classified as an antiviral tablet (400 mg/100 mg) used to treat chronic hepatitis C infection. In Hong Kong, Velpanat is a prescription (Rx) medication regulated under the Medicines and Poisons Ordinance. The tablet form is taken orally, usually once daily.

How Velpanat Works in the Body

• Sofosbuvir is a nucleotide analog that inhibits the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, halting viral RNA synthesis.
• Velpatasvir blocks the NS5A protein, a viral phosphoprotein essential for HCV RNA replication and assembly of new virus particles.
• By targeting two distinct steps in the HCV life cycle, the combination achieves a high barrier to resistance and broad genotype coverage.
• After oral ingestion, the tablet is rapidly absorbed; sofosbuvir is converted intracellularly to its active triphosphate, while velpatasvir reaches peak plasma concentrations within 4-5 hours. Both agents have a half-life compatible with once-daily dosing.

Conditions Treated by Velpanat

• Chronic hepatitis C infection (all genotypes 1-6) in adult patients, as confirmed by laboratory testing.
• The regimen is indicated for treatment-naïve individuals as well as those who have previously received other HCV therapies, provided they meet the prescribing criteria.

Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved this combination for these indications, and Hong Kong’s Department of Health aligns with those standards.

Patient Suitability and Contraindications

• Ideal candidates are adults with confirmed chronic HCV infection who have normal or compensated liver function and no contraindicating conditions.
• Absolute contraindications
• Known hypersensitivity to sofosbuvir, velpatasvir, or any tablet component.
• Co-administration with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, St. John’s wort) that significantly lower velpatasvir exposure.
• Relative contraindications
• Decompensated cirrhosis (Child-Pugh B or C) - dosing may require adjustment and close monitoring.
• Severe renal impairment (eGFR < 30 mL/min/1.73 m²); safety data are limited.
• Special populations
• Pregnancy & lactation: Sofosbuvir and velpatasvir are classified as Category B; use only if the potential benefit outweighs risk and after specialist consultation.
• Elderly: No dose reduction is required solely based on age, but renal and hepatic function should be assessed.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Fatigue, headache, and nausea are the most frequently reported mild reactions.
• Insomnia or mild diarrhea may occur but are usually transient.

Serious Adverse Events

• Rare cases of severe allergic reactions (e.g., angio-edema, Stevens-Johnson syndrome) have been documented; immediate medical attention is required.
• Elevated liver enzymes have been observed in patients with underlying liver disease; monitoring is advised.

Drug Interactions

• Major interactions
• Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John’s wort) markedly reduce velpatasvir levels and should be avoided.
• Moderate interactions
• Certain antiretrovirals (e.g., efavirenz, nevirapine) may modestly decrease velpatasvir exposure; dose adjustment or alternative therapy may be needed.
• Mechanistic note: Velpatasvir is a substrate of P-glycoprotein (P-gp) and CYP3A4; drugs influencing these pathways can alter its plasma concentration.

Patients should provide a complete medication list, including over-the-counter drugs, supplements, and herbal products, to their healthcare provider before initiating Velpanat.

Food and Lifestyle Interactions

• The tablet can be taken with or without food; a high-fat meal does not significantly affect absorption.
• Alcohol consumption should be limited, as it can exacerbate liver injury in HCV patients.
• No specific restrictions on driving or operating machinery; however, severe fatigue should be monitored.

Dosing and Administration Guidelines

• Standard regimen: One Velpanat tablet (400 mg/100 mg) taken orally once daily for 12 weeks.
• Special populations
• Renal impairment: No dose change is required for eGFR ≥ 30 mL/min/1.73 m²; for lower eGFR, specialist evaluation is recommended.
• Hepatic impairment: Patients with Child-Pugh B may follow the same dosing but require close hepatic monitoring; Child-Pugh C is contraindicated.
• Administration tips
• Swallow the tablet whole with a glass of water; crushing is not advised.
• Store tablets at room temperature, away from moisture and direct sunlight.
• Missed dose: Take the missed tablet as soon as remembered on the same day; do not double the next dose.
• Overdose: Symptoms may include severe nausea, vomiting, and dizziness. Seek emergency medical care; supportive care is the mainstay of treatment.
• Discontinuation: Therapy should not be stopped abruptly without medical guidance, as incomplete treatment may lead to viral resistance.

Monitoring and Follow-Up

• Baseline assessments: HCV RNA viral load, liver function tests (ALT, AST), complete blood count, and renal function.
• On-treatment monitoring: HCV RNA at week 4 and week 12 to confirm viral suppression; liver enzymes checked periodically.
• Post-treatment: A sustained virologic response (SVR) is evaluated 12 weeks after completing therapy.
• Patients should contact their healthcare provider if they experience new or worsening symptoms, especially signs of hepatic decompensation.

Storage and Handling

• Keep Velpanat tablets in the original container, tightly closed.
• Store at 20-25 °C (68-77 °F); avoid exposure to excessive heat or humidity.
• Do not use the medication beyond the printed expiration date.
• Dispose of unused tablets according to local pharmacy take-back programs or as directed by the pharmacist.

Medication-Specific Glossary

NS5A inhibitor

A class of antiviral agents that block the hepatitis C virus NS5A protein, disrupting viral replication and assembly.

NS5B polymerase inhibitor

An antiviral that targets the HCV NS5B RNA-dependent RNA polymerase, preventing synthesis of viral RNA.

Sustained virologic response (SVR)

The absence of detectable HCV RNA 12 weeks after completing therapy, considered a cure.

Child-Pugh classification

A scoring system (A-C) used to assess the severity of chronic liver disease and guide medication dosing.

Medical Disclaimer

This article provides educational information about Velpanat and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.